Milestone Pharmaceuticals announced that the FDA has accepted its New Drug Application (NDA) for Cardamyst (etripamil) nasal spray on May 26, 2024, marking a significant step toward a new treatment option for paroxysmal supraventricular tachycardia (PSVT). The FDA has set a Prescription Drug User Fee Act (PDUFA) target date 10 months from the acceptance date.
Addressing PSVT with Cardamyst
Cardamyst is designed as a self-administered therapy, potentially allowing patients to manage PSVT episodes without needing immediate medical intervention. PSVT, characterized by sudden, rapid heartbeats, affects an estimated two million people in the United States. These episodes can cause severe palpitations, shortness of breath, and chest discomfort, significantly impacting daily activities and quality of life.
"The FDA’s acceptance of our NDA for Cardamyst brings Milestone one step closer in our mission in providing a new, convenient and effective treatment option for patients with PSVT," said Joseph Oliveto, President, and Chief Executive Officer of Milestone Pharmaceuticals.
Clinical Data and Development
The Cardamyst clinical trial program represents the largest data package ever studied for an acute drug treatment intended for patient self-management of PSVT events. Milestone is actively preparing for the anticipated launch of etripamil under the brand name Cardamyst, which has been conditionally approved by the FDA.
The Need for New PSVT Treatments
Many healthcare providers express dissatisfaction with current PSVT treatment options, which often involve prolonged and costly emergency department visits or invasive cardiac ablation procedures. Cardamyst aims to fill this gap by providing a rapid-response therapy that patients can self-administer, potentially reducing the burden on healthcare systems and improving patient outcomes.
About Etripamil
Etripamil is a novel calcium channel blocker nasal spray being developed for the treatment of PSVT and AFib-RVR. It is designed to be a self-administered therapy, bypassing the need for immediate medical oversight. The clinical trial program for Cardamyst includes a completed Phase 3 clinical-stage program for the treatment of PSVT and Phase 2 trial for the treatment of patients with AFib-RVR.
